DNA Has Relatively Little Say in Disease Risk (Usually)

Genetic Engineering and Biotechnology News | December 30, 2019

Many diseases have been associated with common gene mutations, or single nucleotide polymorphisms (SNPs). But how well do SNPs or SNP combinations predict disease risk? Not very well at all, say scientists based at the University of Alberta. These scientists, led by David Wishart, PhD, the study’s senior author and a professor of biological sciences and computing science, suggest that disease risk could be better predicted by evaluating clinical, metabolite, or protein measures. “It is becoming increasingly clear,” explained Wishart, “that the risks for getting most diseases arise from your metabolism, your environment, your lifestyle, or your exposure to various kinds of nutrients, chemicals, bacteria, or viruses.”

Spotlight

Vicki Symington (Society for General Microbiology) and John Schollar (National Centre for Biotechnology Education, Reading) demonstrate how to produce a pour plate.

Spotlight

Vicki Symington (Society for General Microbiology) and John Schollar (National Centre for Biotechnology Education, Reading) demonstrate how to produce a pour plate.

Related News

AI

Charles River and Valence Discovery Declare Strategic Partnership to Provide AI-Enabled Drug Design Capabilities to Clients

Valence Discovery, Charles River | April 08, 2021

Charles River Laboratories International, Inc. and Valence Discovery today reported the arrangement of an essential association to give customers admittance to Valence's computerized reasoning stage for sub-atomic property expectation, generative science, and multiparameter improvement. Expanding on research done by Valence's establishing group at Mila, the world's biggest profound learning research organization, the Valence stage empowers the plan of little atom drug up-and-comers in novel districts of compound space, trailed by quick streamlining against project-explicit strength, selectivity, security, and pharmacology rules. Valence has spearheaded the utilization of few-shot learning in drug configuration, permitting the organization to open forecast errands for which just modest quantities of preparing information are accessible, defeating a basic constraint of existing AI advances in drug revelation. Banding together to Accelerate Discoveries By consolidating top tier AI advances with Charles River's start to finish abilities, the coalition can possibly essentially speed up revelation endeavors from hit plan through lead improvement. Through the cooperation, Charles River customers will have the alternative to get to Valence's foundation to help their medication revelation endeavors. When exploiting this alternative, customers can expect expanded variety in substance matter being examined, in mix with more fast improvement against complex, project-explicit plan measures, at last diminishing courses of events and improving achievement rates for drug revelation projects. Affirmed Quotes "This coordinated effort reflects Charles River's continuous obligation to improving our arrangement of creative innovation arrangements. We anticipate utilizing Valence's exceptional stage to improve results for our customers." – Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services, Charles River "The Valence stage offers a stage change improvement over existing again plan advancements. We've been reliably intrigued by Valence Discovery's capacity to create top notch synthetic matter that is promptly synthesizable, in novel areas of compound space, from datasets not in any case open to AI strategies." – Grant Wishart, PhD, Director of Computer Aided Drug Design, Charles River "We are excited to collaborate with Charles River, a worldwide pioneer trusted by numerous individuals of the world's top drug and biotech organizations. This cooperation is a significant advance in facilitating our central goal of engaging each medication disclosure researcher with the most recent developments in AI-empowered medication plan."– Daniel Cohen, CEO of Valence Discovery About Valence's AI-Enabled Drug Design Platform The Valence stage develops the scholarly community driving exploration done by the organization's establishing group at Mila, the world's biggest profound learning research foundation. Specifically, Valence has spearheaded the use of not many shot learning in drug configuration, permitting the organization to open forecast assignments for which just limited quantities of preparing information are accessible, including novel targets and complex ADME models, while additionally guaranteeing that AI-produced particles are of high therapeutic science quality and promptly synthesizable. Also, Valence utilizes dynamic learning and iterative improvement procedures to guarantee that lone the most data rich mixtures are chosen for amalgamation, empowering the plan of mixtures meeting the objective strength, selectivity, and ADME models in less emphasess, and with undeniably less information, than in any case conceivable. About Valence Discovery Valence is focused on opening the genuine capability of profound learning in drug plan by binding together top tier profound learning innovations with instinctive foundation to make these advances all the more extensively open to R&D associations, everything being equal. Valence's AI-empowered medication plan stage has been widely approved and is right now being utilized to distinguish and configuration drug applicants as a team with industry-driving accomplices. The organization is spearheading the utilization of few-shot learning in drug plan and is creating and conveying novel AI strategies for sub-atomic property expectation, generative science, and multiparameter advancement. Valence (once in the past InVivo AI) was established in 2018, is exhorted by profound learning pioneer, Dr. Yoshua Bengio, and is gladly settled in Montreal at Mila, the world's biggest profound learning research foundation, with an office in Cambridge, Mass. About Charles River Charles River gives fundamental items and administrations to help drug and biotechnology organizations, government offices and driving scholastic foundations all throughout the planet speed up their exploration and medication improvement endeavors. Our devoted workers are centered around giving customers precisely what they need to improve and assist the disclosure, beginning phase advancement and safe production of new treatments for the patients who need them.

Read More

INDUSTRIAL IMPACT

ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships

ShouTi Inc | February 18, 2022

ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships. Basecamp Bio integrates unique insights, skills, technological know-how and experience to navigate the complex challenges of membrane protein structure-based drug discovery. Its mission is to prosecute the most challenging structure-based drug discovery targets, including G-protein coupled receptors (GPCRs), and deliver discovery assets to ShouTi’s development pipeline. In addition, Basecamp Bio will explore selective partnerships to tackle high value targets pursued by the biopharmaceutical industry. Basecamp Bio is led by Yingli Ma, Ph.D., President, who brings close to 15 years of research, technology, and drug discovery experience including her previous role as general manager of Amgen Shanghai Research Center. Dr. Ma led Amgen’s global structural biology and drug discovery programs in cardiometabolic and inflammatory diseases. “By bringing together our deep expertise in structure-based drug design with leading drug discovery technologies, we aim to create orally-available small molecule medicines against some of the most complex targets including those validated by biologics,” said Dr. Ma. “With all of these breakthrough technologies under one roof, and access to the Shanghai biotech contract research organization ecosystem as a resource, Basecamp Bio has the ability to greatly accelerate the discovery of assets with best-in-class potential.” Basecamp Bio’s technology leverages the power of cryo-electron microscopy, machine learning and X-ray crystallography, as the basis for its molecular designs. The company employs state-of-the-art small molecule hit identification, including DNA encoded library technology and affinity mass spectrometry selections for membrane proteins. This is integrated with cutting-edge computational chemistry and medicinal chemistry along with a matrix of pharmacological assay platforms. ShouTi’s exceptional experience with cell surface receptor signaling and pharmacology will further enable Basecamp Bio to achieve its goal of designing medicines with optimal pharmaceutical properties to address patient needs. “Given the broad potential of the platform and our team’s deep expertise with challenging drug targets, we are excited to deploy Basecamp Bio to both advance our own pipeline and enable early-stage drug discovery partnerships to extend the reach of our leading-edge science,” Melita Sun Jung, Chief Business Officer, ShouTi About ShouTi ShouTi is a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company’s cutting-edge technology platform leverages structure-based drug discovery and computational chemistry expertise and enables ShouTi to develop oral small molecule therapeutics for the treatment of various diseases, including those in the metabolic, cardiovascular, and pulmonary therapeutic areas. By leveraging ShouTi’s world-class GPCR know-how, the company aims to design differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies targeting this family of receptors.

Read More

Research Solutions Announces Partnership with BIO Business Solutions to Bring One-Click Scientific Literature Access to the Biotech Industry

Research Solutions | October 12, 2020

Research Solutions/Reprints Desk (NASDAQ: RSSS), a pioneer in providing cloud-based workflow solutions for R&D driven organizations, today announced that it has partnered with BIO Business Solutions to help life sciences companies save time and money on scholarly literature access via its award-winning Article Galaxy research platform. Operated by the Biotechnology Innovation Organization (BIO), BIO Business Solutions is the industry's largest cost savings purchasing program. More than 4,500 member companies worldwide—including biotechnology and biopharmaceutical firms, medical device firms, academic institutions, state biotechnology centers, and related organizations—together save more than $511 million annually through the BIO Business Solutions® program.

Read More